Q3 2025 Insight Molecular Diagnostics Inc Earnings Call Transcript

Nov 10, 2025 / 10:00 PM GMT

Release Date Price: $6.8 (+8.97%)

Transcript 10-Q8-K

Key Points

Positve

Insight Molecular Diagnostics Inc (IMDX) is on track for FDA submission of their Graftassure DX test by the end of 2025, which could revolutionize transplant patient management.
The company has successfully optimized their test workflow from two steps to one, improving turnaround time and ease of use.
Preliminary results from studies show that Graftassure DX performs well compared to existing technologies, indicating strong potential for market adoption.
The company has launched a registry program to capture real-world data, which could enhance clinician familiarity and support broader adoption.
Insight Molecular Diagnostics Inc (IMDX) has maintained a strong financial position with $20 million in cash and no debt, allowing them to continue their R&D investments.

Negative

The FDA review process could be delayed due to the government shutdown, potentially impacting the timeline for regulatory approval and commercial launch.
The company faces challenges in converting early adopter physicians to center-wide adoption, as clinicians may require head-to-head comparisons with existing technologies.
There is uncertainty regarding the finalization of the LCD by Palmetto GBA, which could affect reimbursement rates and market opportunity.
The company's cash burn is expected to increase in Q4 due to FDA submission and clinical trial expenses, which could strain financial resources.
Enrollment for clinical trials is progressing slower than desired, which may impact the timeline for data submission and subsequent FDA approval.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMDX.OQ - Insight Molecular Diagnostics Inc
Q3 2025 Insight Molecular Diagnostics Inc Earnings Call
Nov 10, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
All right, go ahead.

Mm.

Eric, it says we're still in practice session. Do you have to kick off the meeting? Okay, there we go.

All right, everyone.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
And welcome everyone and thank you for joining us to discuss Insight Molecular's Diagnostics, 3rd quarter 2025 results.

If you have not seen today's shareholder letter, please visit Insight Molecular Diagnostics Investor relations page at investors.

IMDXNC.com.

Today's prepared remarks build upon the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.